ClinicalTrials.gg
CompletedNCT00274469FIRSTUpdated Sep 6, 2019Results posted

A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer

A Phase 2 interventional study of fulvestrant and anastrozole in Metastatic Breast Cancer, sponsored by AstraZeneca. Completed at 41 sites in 9 countries. Open to female participants aged 45 Years to 100 Years. Per ClinicalTrials.gov, last updated 2019-09-06.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
45 Years to 100 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
23rd of 94
205 · median 71
Started
2006
with 4 others
Phase 2
59 of 95
8 open now
Registered
19th of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 23rd largest by enrollment of the 94 interventional ones that give a count, is one of 5 that started in 2006, is one of 59 in phase 2, and was the 19th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 45 Years to 100 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor positive advanced breast cancer.

03

Conditions studied

  • Metastatic Breast Cancer

Keywords

  • oncology
  • cancer
  • breast cancer
04

Who can participate

Ages eligible
45 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed hormone receptor positive advanced breast cancer, women

Exclusion criteria

Exclusion Criteria:

  • Previous treatment for advanced breast cancer (previous treatment for early breast cancer is allowed).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    1

    Fulvestrant

    Drug: fulvestrant

  • Active comparator
    2

    Anastrozole

    Drug: anastrozole

Interventions

  • 500 mg intramuscular injection

    Also known as: Faslodex, ZD9238

  • 1 mg oral tablet

    Also known as: Arimidex, ZD1033

06

What researchers measure

Primary outcomes

  1. Clinical Benefit Rate

    A Clinical Benefit (CB) responder is defined as a patient having a best overall response of either complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks evaluated according to modified RECIST. The Clinical Benefit Rate is the percentage of patients with CB.

    Time frame: From randomisation to data cut off (DCO) for primary analysis. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007 respectively. The DCO for primary analysis was on 10th Jan 2008, 6 months after the last patient was enrolled.

Secondary outcomes

  1. Objective Response Rate

    For each patient with measurable disease at baseline, the determination of the overall response for each visit was carried out using a SAS program per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Complete Response (CR): Disappearance of all target lesion (TL) and non-target lesions (NTLs) and no new lesions. Partial Response (PR): At least a 30% decrease in the sum of longest diameter of TLs (compared to baseline), no progression of NTLs and no new lesions. Objective response rate is defined as percentage of patients with either CR or PR.

    Time frame: From randomisation to data cut off (DCO) for primary analysis. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007 respectively. The DCO for primary analysis was on 10th Jan 2008, 6 months after the last patient was enrolled.

  2. Time to Progression

    Time from randomization until earlier of disease progression or death. Progression was defined according to RECIST: a patient is determined to have progressed if they have progression of target lesions, clear progression of existing non-target lesions, or the appearance of one or more new lesions. Progression of target lesions is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum of LD recorded. Kaplan-Meier estimates of median for each treatment are reported.

    Time frame: From randomisation to data cut off (DCO) for primary analysis. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007 respectively. The DCO for primary analysis was on 10th Jan 2008, 6 months after the last patient was enrolled.

  3. Time to Treatment Failure

    Time from randomization to treatment discontinuation

    Time frame: From randomisation to data cut off (DCO) for 75% treatment failure. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007. The DCO for 75% treatment failure was on 26 Mar 2010, 32 months after the last patient was enrolled.

  4. Time to Progression (Investigator Assessed)

    Time from randomization to disease progression (investigator assessed) or death from any cause. Progression was defined by investigator opinion, as patients did not have formal RECIST visits in the follow-up period after the data cut off for the primary analysis of the study.

    Time frame: From randomisation to data cut off (DCO) for 75% treatment failure. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007. The DCO for 75% treatment failure was on 26 Mar 2010, 32 months after the last patient was enrolled.

07

Results

Posted Aug 12, 2009
Limitations and caveats
One patient in the ITT population was randomized to Fulvestrant 500 but did not receive drug and was excluded from the safety population. Hence, the safety population for Fulvestrant contained 101 patients.

Participant flow

Postmenopausal women presenting with advanced breast cancer who had either never received endocrine therapy for advanced disease or had not received endocrine therapy in the previous 12 months in the adjuvant setting were recruited between 6th Feb 2006 and 11th July 2007.

Participant flow — Overall Study
MilestoneFulvestrant 500 mgAnastrozole 1 mg
Started102103
Completed2310
Not completed7993
Withdrew: Death6374
Withdrew: Did not consent to os follow-up1619

Outcome measures

PrimaryClinical Benefit Rate

A Clinical Benefit (CB) responder is defined as a patient having a best overall response of either complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks evaluated according to modified RECIST. The Clinical Benefit Rate is the percentage of patients with CB.

Time frame:
From randomisation to data cut off (DCO) for primary analysis. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007 respectively. The DCO for primary analysis was on 10th Jan 2008, 6 months after the last patient was enrolled.
Reported as:
Number · Percentage of Participants
Clinical Benefit Rate
Percentage of ParticipantsFulvestrant 500 mgAnastrozole 1 mg
Clinical Benefit Rate72.567.0
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Regression, Logistic · p = 0.386 (Null hypothesis: Fulvestrant has no difference with Anastrozole) · Odds ratio (or): 1.302 · 95% CI 0.717 to 2.380OR\>1 favours Fulvestrant
SecondaryObjective Response Rate

For each patient with measurable disease at baseline, the determination of the overall response for each visit was carried out using a SAS program per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Complete Response (CR): Disappearance of all target lesion (TL) and non-target lesions (NTLs) and no new lesions. Partial Response (PR): At least a 30% decrease in the sum of longest diameter of TLs (compared to baseline), no progression of NTLs and no new lesions. Objective response rate is defined as percentage of patients with either CR or PR.

Time frame:
From randomisation to data cut off (DCO) for primary analysis. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007 respectively. The DCO for primary analysis was on 10th Jan 2008, 6 months after the last patient was enrolled.
Reported as:
Number · Percentage of Participants
Objective Response Rate
Percentage of ParticipantsFulvestrant 500 mgAnastrozole 1 mg
Objective Response Rate36.035.5
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Regression, Logistic · p = 0.947 · Odds ratio (or): 1.021 · 95% CI 0.556 to 1.874OR\>1 favours Fulvestrant
SecondaryTime to Progression

Time from randomization until earlier of disease progression or death. Progression was defined according to RECIST: a patient is determined to have progressed if they have progression of target lesions, clear progression of existing non-target lesions, or the appearance of one or more new lesions. Progression of target lesions is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum of LD recorded. Kaplan-Meier estimates of median for each treatment are reported.

Time frame:
From randomisation to data cut off (DCO) for primary analysis. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007 respectively. The DCO for primary analysis was on 10th Jan 2008, 6 months after the last patient was enrolled.
Reported as:
Median · Day
Time to Progression
DayFulvestrant 500 mgAnastrozole 1 mg
Time to ProgressionNA (173 to NA)381 (168 to NA)
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Log Rank · p = 0.0496 · Hazard ratio (hr): 0.6266 · 95% CI 0.3929 to 0.9991HR\<1 favours Fulvestrant
SecondaryTime to Treatment Failure

Time from randomization to treatment discontinuation

Time frame:
From randomisation to data cut off (DCO) for 75% treatment failure. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007. The DCO for 75% treatment failure was on 26 Mar 2010, 32 months after the last patient was enrolled.
Reported as:
Median · Day
Time to Treatment Failure
DayFulvestrant 500 mgAnastrozole 1 mg
Time to Treatment Failure536 (166 to 1303)387 (169 to 838)
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Log Rank · p = 0.05 · Hazard ratio (hr): 0.73 · 95% CI 0.54 to 1.00HR\<1 favours Fulvestrant
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Regression, Cox · p = 0.04 · Hazard ratio (hr): 0.72 · 95% CI 0.52 to 0.98HR\<1 favours Fulvestrant
SecondaryTime to Progression (Investigator Assessed)

Time from randomization to disease progression (investigator assessed) or death from any cause. Progression was defined by investigator opinion, as patients did not have formal RECIST visits in the follow-up period after the data cut off for the primary analysis of the study.

Time frame:
From randomisation to data cut off (DCO) for 75% treatment failure. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007. The DCO for 75% treatment failure was on 26 Mar 2010, 32 months after the last patient was enrolled.
Reported as:
Median · Day
Time to Progression (Investigator Assessed)
DayFulvestrant 500 mgAnastrozole 1 mg
Time to Progression (Investigator Assessed)712 (173 to 1331)400 (168 to 908)
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Log Rank · p = 0.01 · Hazard ratio (hr): 0.66 · 95% CI 0.47 to 0.92HR\<1 favours Fulvestrant
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Regression, Cox · p = 0.01 · Hazard ratio (hr): 0.64 · 95% CI 0.46 to 0.90HR\<1 favours Fulvestrant
Post-hocOverall Survival

Time from randomization to death (any cause)

Time frame:
From randomization to data cut off (DCO) for 65% OS analysis. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007 respectively. The DCO for 65% OS analysis was on 15 Jul 2014, 7 years after the last patient was enrolled.
Reported as:
Median · Month
Overall Survival
MonthFulvestrant 500 mgAnastrozole 1 mg
Overall Survival54.1 (29.7 to NA)48.4 (28.6 to 78.5)
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Log Rank · p = 0.041 · Hazard ratio (hr): 0.70 · 95% CI 0.50 to 0.98
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Regression, Cox · p = 0.126 · Hazard ratio (hr): 0.76 · 95% CI 0.54 to 1.08HR\<1 favours Fulvestrant

Adverse events

Collected over Non-serious adverse events = randomisation upto the point of data cut off for the primary efficacy analysis. Serious adverse events = randomisation up to the point of data cut off for the 65% overall survival analysis.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fulvestrant 500 mg63/102 (61.8%)24/101 (23.8%)71/101 (70.3%)
Anastrozole 1 mg74/103 (71.8%)22/103 (21.4%)70/103 (68%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventFulvestrant 500 mgAnastrozole 1 mg
DYSPNOEARespiratory, thoracic and mediastinal disorders2/1010/103
CARDIAC FAILURECardiac disorders2/1010/103
DECREASED APPETITEMetabolism and nutrition disorders2/1010/103
DEHYDRATIONMetabolism and nutrition disorders2/1010/103
FEMUR FRACTUREInjury, poisoning and procedural complications1/1012/103
TRANSIENT ISCHAEMIC ATTACKNervous system disorders0/1012/103
DEATHGeneral disorders0/1012/103
ATRIAL FIBRILLATIONCardiac disorders1/1011/103
BRONCHITISInfections and infestations1/1010/103
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders1/1010/103
Most frequent other events
Showing 10 of 201
Most frequent other events
EventFulvestrant 500 mgAnastrozole 1 mg
BONE PAINMusculoskeletal and connective tissue disorders14/10110/103
HOT FLUSHVascular disorders8/10114/103
HEADACHENervous system disorders4/10113/103
ARTHRALGIAMusculoskeletal and connective tissue disorders10/1018/103
CONSTIPATIONGastrointestinal disorders10/1015/103
NAUSEAGastrointestinal disorders10/1017/103
MYALGIAMusculoskeletal and connective tissue disorders3/1019/103
VOMITINGGastrointestinal disorders8/1013/103
ASTHENIAGeneral disorders8/1018/103
COUGHRespiratory, thoracic and mediastinal disorders5/1018/103

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fulvestrant 500 mgAnastrozole 1 mgTotal
Mean66.6 ± 9.067.6 ± 9.367.1 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Fulvestrant 500 mgAnastrozole 1 mgTotal
Female102103205
Male000
08

Study locations

41 sites
  • Research Site
    Frederick, Maryland 21701, United States
  • Research Site
    Saint Louis, Missouri 63113, United States
  • Research Site
    Teaneck, New Jersey 07666, United States
  • Research Site
    Austin, Texas 78705, United States
  • Research Site
    Duncanville, Texas 75137, United States
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Belo Horizonte, 30380-490, Brazil
  • Research Site
    Goiânia, 74000-000, Brazil
  • Research Site
    Jaú, 17210-120, Brazil
  • Research Site
    Rio de Janeiro, 20560-120, Brazil
  • Research Site
    Sao Paulo, 01219-010, Brazil
  • Research Site
    Blagoevgrad, 2700, Bulgaria
  • Research Site
    Plovdiv, 4000, Bulgaria
  • Research Site
    Shumen, 9700, Bulgaria
  • Research Site
    Sofia, 1233, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Sofia, 1784, Bulgaria
  • Research Site
    Varna, 9000, Bulgaria
  • Research Site
    Veliko Tarnovo, 5000, Bulgaria
  • Research Site
    Vratza, 3000, Bulgaria
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Brno, 656 91, Czechia
  • Research Site
    Jicin, 506 43, Czechia
  • Research Site
    Ostrava, 708 52, Czechia
  • Research Site
    Praha 4, 140 00, Czechia
  • Research Site
    Usti nad Labem, 401 13, Czechia
  • Research Site
    Nice, 06100, France
  • Research Site
    Poitiers, 86000, France
  • Research Site
    Saint-cloud, 92210, France
  • Research Site
    Napoli, 80131, Italy
  • Research Site
    Sassari, 07100, Italy
  • Research Site
    Kraków, 31-115, Poland
  • Research Site
    Olsztyn, 10-228, Poland
  • Research Site
    Barcelona, 08003, Spain
  • Research Site
    Barcelona, 08025, Spain
  • Research Site
    Córdoba, 14004, Spain
  • Research Site
    Lérida, 25198, Spain
  • Research Site
    Pontevedra, 36002, Spain
  • Research Site
    Derby, DE22 3DT, United Kingdom
  • Research Site
    Dundee, DD1 9SY, United Kingdom
  • Research Site
    Edinburgh, EH4 2XU, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2006 to primary completion in Jan 2008, 23 months.

Results were first posted in Aug 2009, 1 year 7 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 23 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2006
First posted
Jan 11, 2006
StartActual
Feb 6, 2006
Primary completionActual
Jan 10, 2008
CompletionActual
Jan 13, 2017
Results first posted
Aug 12, 2009
Last update
Sep 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00274469
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 11, 2006
Start date
Feb 6, 2006
Primary completion
Jan 10, 2008
Completion
Jan 13, 2017
Results posted
Aug 12, 2009
Last update
Sep 6, 2019

Study contacts

AstraZeneca Faslodex Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion